Key result
The HTR1A rs6295 polymorphism showed no significant difference in genotypic or allelic frequencies between schizophrenia patients with and without tardive dyskinesia.
Case-Control (n=280)
Yes
Answers are grounded in this paper and cite their sources.
Tardive dyskinesia affects a substantial share of antipsychotic-treated schizophrenia patients; leaves open optimal prevention and management strategies pending higher-level evidence.
서 론 조현병 치료에 있어서 항정신병약물은 필수적인 약물 중에 하나로 알려져 있으며 항정신병 약물을 복용하는 환자 중 29~74% 정도에서 추체외로부작용(extrapyramidal symptoms)이 발생한다고 보고되고 있다. 1) 추체외로부작용으로는 급성 근긴장이상(acute dystonia), 정좌불능증(akathisia), 파 킨슨증(parkinsonism)과 지연성 운동이상(tardive dyskinesia)가 있으며 조현병으로 항정신병 약물을 복용하는 환자 의 20%에서 지연성 운동이상(neuroleptic-induced tardive dyskinesia)
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) conducted a case-control in Schizophrenia with tardive dyskinesia (n=280). HTR1A rs6295 polymorphism vs. Schizophrenia patients without tardive dyskinesia was evaluated on Difference in genotypic frequency of HTR1A rs6295 (p=0.26). The HTR1A rs6295 polymorphism showed no significant difference in genotypic or allelic frequencies between schizophrenia patients with and without tardive dyskinesia.
Synapse has enriched 10 related papers. Consider them for comparative context: